Notably, chronic GVHD was more frequently observed in the higher CD34+ cell dose group (46.2%) compared to the adequate CD34+ cell dose group (23.3%) (P = 0.048), suggesting a potential association between increased stem cell dose and a higher risk of chronic GVHD. The gene discussed is CD34; the disease is chronic graft versus host disease.